News

New approach resets MS
Enlarge image

ResearchAustriaGermanySwitzerland

New approach resets MS

06.06.2013 - An international research team has found a way to calm the autoimmune reaction that leads to myelin destruction in Multiple Sclerosis patients.

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and reduced patients' immune system reactivity to myelin by 50 to 75 percent. In 9 patients, the researchers from Hamburg, Vienna, Zürich, and Chicago succeeded to reduce the autoimme reaction against myelin, which surrounds neurons like an insulator. They did so by coupling 7 myelin antigens thought to induce MS to the patients’ white blood cells ex vivo, which induced immune tolerance after reinjection in their bloodstream. Most of the patients who received high doses of the antigen-coupled blood cells did not show any new brain lesions or symptomatic relapses up to the end of the study’s six month follow-up period (Science Translat. Medicine, 5 May, 2013).

"The therapy stops autoimmune responses that are already activated and prevents the activation of new autoimmune cells," said co-author Stephen Miller from Northwestern University Feinberg School of Medicine. "Our approach leaves the function of the normal immune system intact. That's the holy grail." According to lead author Andreas Lutterotti from Innsbruck Medical University/Medical Center Hamburg-Eppendorf, the dead lymphocytes carrying the myelin antigens are filtered out of the blood in the spleen. During this process, immune cells start to recognise the myelin antigens as harmless and immune tolerance quickly develops. They confirmed this in patients by immune assays.

Although the patient numbers are small in this first-in-human study, the safety, feasibility, and early results suggest that this approach may provide a promising avenue for future trials. Unlike current immunosuppressive drugs for MS, the new approach does not compromise the immune system’s infection-fighting abilities. The process mimics a natural process by which millions of red and white blood cells, which normally die each day, are cleared from the bloodstream without alerting the immune system.  

The human safety study sets the stage for a phase 2 trial to see if the new treatment can prevent the progression of MS in humans. Scientists are currently trying to raise $1.5 million to launch the trial, which has already been approved in Switzerland. The new approach may be useful for treating not only MS but also a host of other autoimmune and allergic diseases simply by switching the antigens attached to the cells.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/new-approach-resets-ms.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON13.90 EUR12.10%
  • MAGFORCE5.10 EUR7.82%
  • SANTHERA103.00 CHF5.64%

FLOP

  • CYTOS0.32 CHF-17.95%
  • CO.DON2.15 EUR-4.44%
  • MEDIGENE3.80 EUR-4.28%

TOP

  • ADDEX3.44 CHF47.6%
  • CYTOS0.32 CHF45.5%
  • FORMYCON13.90 EUR39.1%

FLOP

  • ACTELION100.70 CHF-15.1%
  • MOLOGEN5.72 EUR-13.7%
  • BIOFRONTERA2.02 EUR-12.2%

TOP

  • SANTHERA103.00 CHF2494.5%
  • BB BIOTECH248.45 EUR96.5%
  • FORMYCON13.90 EUR80.5%

FLOP

  • CYTOS0.32 CHF-90.3%
  • 4SC0.82 EUR-50.9%
  • MOLOGEN5.72 EUR-50.8%

No liability assumed, Date: 27.01.2015